The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Enoby denosumab-qbde Biosimilar | Hikma Pharmaceuticals Usa Inc | 🇺🇸 US 2025-09-26 | Order → | |
| Inluriyo imlunestrant tosylate New molecular entity | Eli Lilly And Co | 🇺🇸 US 2025-09-25 | Order → | |
| Palsonify paltusotine hydrochloride New molecular entity | Crinetics | 🇺🇸 US 2025-09-25 | Order → | |
| Bondlido lidocaine New formulation or manufacturer | Medrx Usa | 🇺🇸 US 2025-09-24 | Order → | |
| Kisunla donanemab Additional monitoring | Eli Lilly Nederland B.V. | Alzheimer Disease; Cognitive Dysfunction | 🇪🇺 EU 2025-09-24 | Order → |
| Macitentan Accord macitentan Generic | Accord Healthcare | Hypertension, Pulmonary | 🇪🇺 EU 2025-09-24 | Order → |
| Macitentan AccordPharma macitentan Generic | Accord Healthcare | Hypertension, Pulmonary | 🇪🇺 EU 2025-09-24 | Order → |
| Bildyos denosumab BiosimilarAdditional monitoring | Sciencepharma Sp. z o.o | Bone Resorption; Osteoporosis, Postmenopausal; Osteoporosis | 🇪🇺 EU 2025-09-17 | Order → |
| Bilprevda denosumab BiosimilarAdditional monitoring | Sciencepharma Sp. z o.o | Giant Cell Tumor of Bone; Neoplasms, Bone Tissue | 🇪🇺 EU 2025-09-17 | Order → |
| Ekterly sebetralstat OrphanAdditional monitoring | Kalvista Pharmaceuticals (Ireland) Limited | Angioedemas, Hereditary | 🇪🇺 EU 2025-09-17 | Order → |
| Romvimza vimseltinib OrphanAdditional monitoring | Deciphera Pharmaceuticals (Netherlands) B.V. | Giant Cell Tumor of Tendon Sheath | 🇪🇺 EU 2025-09-17 | Order → |
| Tryngolza olezarsen Additional monitoring | Swedish Orphan Biovitrum AB (publ) | Hyperlipoproteinemia Type I | 🇪🇺 EU 2025-09-17 | Order → |
| Usrenty ustekinumab BiosimilarAdditional monitoring | Biosimilar Collaborations Ireland Limited | Crohn Disease | 🇪🇺 EU 2025-09-17 | Order → |
| Voranigo vorasidenib OrphanAdditional monitoring | Les Laboratoires Servier | Oligodendroglioma; Astrocytoma | 🇪🇺 EU 2025-09-17 | Order → |
| Eyluxvi aflibercept BiosimilarAdditional monitoring | Biolitec pharma Limited Zweigniederlassung Jena | Wet Macular Degeneration; Macular Edema; Diabetes Complications; Retinal Vein Occlusion | 🇪🇺 EU 2025-09-15 | Order → |
| Yeytuo lenacapavir | Gilead Sciences Ireland Unlimited Company | HIV Infections; HIV-1 | 🇪🇺 EU 2025-08-25 | Order → |
| Zemcelpro allogeneic umbilical cord-derived CD34- cells, non-expanded;dorocubicel OrphanPRIMEATMP | Cordex Biologics International Limited | Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation | 🇪🇺 EU 2025-08-25 | Order → |
| Nintedanib Viatris nintedanib Generic | Viatris Limited | Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis | 🇪🇺 EU 2025-08-22 | Order → |
| Imreplys sargramostim Exceptional circumstancesAdditional monitoring | Partner Therapeutics Limited | Acute Radiation Syndrome | 🇪🇺 EU 2025-08-21 | Order → |
| Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris emtricitabine;rilpivirine;tenofovir alafenamide Generic | Viatris Limited | HIV Infections | 🇪🇺 EU 2025-08-19 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.